An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis
- Sponsor
- Samsung Bioepis Co., Ltd.
- Study ID
- NCT02565810
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Not accepted
Interventions
- Adalimumab PFS and Pen — DRUG
Study Details
A study comparing the use of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects with Rheumatoid Arthritis.
Key Dates
- Start date
- Sep 30, 2015
- Status verified
- Dec 2018
- Primary completion
- Mar 31, 2016
- Completion
- Mar 31, 2016
Study Design
- Enrollment
- 49 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: SB5 40mg
Primary Outcome Measure
The Change in Injection Site Pain Score Using an 11-point Visual Numeric Scale [ Time Frame: Difference of injection site pain score (Week 6 - Week 2) ]
Related Studies
- CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness RegistryEnrolling By Invitation · CorEvitas · Waltham, Massachusetts
- Physica System Total Knee Replacement Registry StudyRecruiting · Limacorporate S.p.a · Rancho Mirage, California
- Early Rheumatoid Arthritis Lung Disease StudyRecruiting · University of Nebraska · Omaha, Nebraska
- Maternal Autoimmune Disease Research Alliance (MADRA) RegistryRecruiting · Duke University · Durham, North Carolina